Device Trial Radar · NCT05064709
Assessment of CCM in HF With Higher Ejection Fraction
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,500
Planned (sponsor's estimate)
Start
Feb 3, 2022
Primary completion
Feb 1, 2029
Study completion Feb 1, 2029
Sponsor
- Lead sponsor
- Impulse DynamicsNot on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 1, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.
Conditions
- Heart Failure
- Heart Failure With Preserved Ejection Fraction
- Heart Failure With Mid Range Ejection Fraction
- Heart Failure With Moderately Reduced Ejection Fraction
- Diastolic Heart Failure
Interventions
Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini SystemDevice
The OPTIMIZER™ Smart Mini System will be implanted and CCM will be programmed ON for the first 18 months (blinded phase). CCM therapy will be programmed to deliver 7 one-hour phases of CCM therapy that are distributed equally over every 24-hour period. CCM will remain on following completion of the 18-month visit.
OPTIMIZER™ Smart Mini SystemDevice
The OPTIMIZER™ Smart Mini System will be implanted and CCM will be programmed OFF for the first 18 months (blinded phase). CCM will be turned on following completion of the 18-month visit.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 Efficacy Endpoint - Change in 6-minute walk distance (6MWD) from baseline to 6 months.Time frame: 6 months
- Part 1 Efficacy Endpoint - Change in the health status from baseline to 6 months as assessed by the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ CSS).Time frame: 6 months
- Part 1 Safety Endpoint - The incidence of Optimizer device- or procedure-related complications within the first 12 months after implantTime frame: 12 months
1 more outcomes with a free account
Locations
67 sites in 1 country. Site status is shown where the registry gives one.
Grandview Medical Group Research, LLC
Birmingham, Alabama · Recruiting
CardioVascular Associates of Mesa
Mesa, Arizona · Recruiting
Southwest Cardiovascular Associates
Mesa, Arizona · Recruiting
64 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.